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Volume 61, Number 2 Abstracts 575by cardiothoracic surgeons, 8.0% by interventional radiologists, and the
remainder by interventional cardiologists and general surgeons (Table I).
Interventional cardiologists and general surgeons had too low of a sample
size for valid statistical analysis. Interventional radiologists had signiﬁcantly
more elective cases (77.8%; P < .001) than cardiothoracic surgeons (47.2%)
or vascular surgeons (53.8%), but had a signiﬁcantly higher rate of stroke
(7.6% vs 1.1%; P< .001), cardiac events (7.2% vs 3.6%; P< .001), respiratory
complications (4.8% vs 1.9%; P< .001), vascular complications (7.5% vs 2.6%;
P < .01), and surgical site infection (2.8% vs 0.8%; P < .01). Despite these
complications, length of stay (10.7 days) and median costs ($52,156) were
similar across the three specialties. Cardiothoracic surgeons completing
TEVAR have the highest mortality rate (8.6% vs 2.6%; P< .01). Vascular sur-
geons have a low stroke rate (1.1%; P< .05 vs interventional radiologists) and
lower rate of cardiac events (3.6% vs 6.1%; P< .01) despite caring for patients
with higher Diagnosis-Related Group mortality scores (3.6 vs 3.4; P < .05).
Conclusions: Physician specialty affects patient outcome after
TEVAR. Vascular surgeons have the lowest overall morbidity after TEVAR
compared with the other specialties and lower mortality compared with
cardiothoracic surgeons. These ﬁndings may affect patient referral patterns
and hospital privileges for providers.
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Israel Deaconess Medical Center, Boston, MassFig. Relative rate of 1-year amputation and revascularization risk bas
Infection (WIfI) classiﬁcation system.Objectives: The Society for Vascular Surgery (SVS) Lower Extremity
Guidelines Committee has composed a new threatened lower extremity
classiﬁcation system that reﬂects the three major factors that affect amputa-
tion risk and clinical management: Wound, Ischemia, and foot Infection
(WIfI). Our goal was to evaluate the predictive ability of this scale after
any infrapopliteal endovascular intervention for critical limb ischemia (CLI).
Methods: From2004 to 2014, 673patients underwent an infrapopliteal
endovascular intervention for tissue loss (77%), rest pain (13%), stenosis of a pre-
viously treated vessel (5%), acute limb ischemia (3%), or claudication (2%). Pa-
tientswithout an initial grade in allWIfI categorieswere excluded.Patientswere
stratiﬁed both into clinical stages 1 to 4 based on the SVSWIfI classiﬁcation for
1-year amputation and revascularization risk as well as a novel composite score
from 0 to 9. Outcomes included the SVS objective performance goals (major
amputation, amputation-free survival, and wound healing) as well as mortality
andRAS events (revascularization,major amputation, or stenosis [>3.5 step-
upbyduplex]). Analyseswereperformedusingmultivariable logistic regression,
Cox regression models, and Kaplan-Meier survival estimates.
Results: Of the 596 CLI patients, 551 were classiﬁed in all three WIfI
domains on a scale of 0 (least severe) to 3 (most severe). Of these 551 patients,
84% were treated for tissue loss and 16% for rest pain. A Cox regression model
illustrated that an increase of 1 clinical stage increases the rate of major ampu-
tation (hazard ratio [HR], 1.4; 95% conﬁdence interval [CI], 1.0-2.0). A sepa-
rate regression model showed that a 1-unit increase in the composite WIfI
scale is associated with an increase in the rate of RAS events (HR, 1.2; 95%
CI, 1.1-1.3) and a decrease in wound healing (HR, 1.2; 95% CI, 1.0-1.3).
Conclusions: This study suggests that the SVS WIfI classiﬁcation sys-
tem can predict 1-year amputation, RAS events, and wound healing after
any endovascular infrapopliteal intervention for CLI (Fig).
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Objectives: Percutaneousmechanical thrombectomy (PMT) is a popu-
lar and useful tool for thrombus removal in acute thrombotic syndromes. The
AngioJet uses high-pressure spray to break up and aspirate thrombus in addi-
tion to delivering plasminogen activators. This is known to cause hemolysis,
and all practitioners have noted periprocedural hematuria. Despite this, to
our knowledge, there is no study evaluating the consequences to renal function
after using this device. We sought to determine the incidence of acute kidney
injury, and associated risk factors after using the AngioJet for thrombolysis.
Methods: With Investigational Review Board approval, we retrospec-
tively reviewed a prospectively maintained database of all patients managed
by the vascular surgery service from 2009-2012 with procedural codes
describing thrombolysis (Current Procedural Terminology [CPT] codes
37201, 37187, 37209, and 75898), and/or PMT (CPT 37187). We iden-
tiﬁed those treated with the AngioJet and reviewed demographics, indica-
tions, laboratory values before and after the procedure (up to 3 days), and
determined the incidence of acute kidney injury (AKI). AKI was deﬁned
as an increase in creatinine (Cr) >25% of baseline within 24 to 72 hours.
Patients on dialysis before AngioJet or without laboratory values before
and 24 to 72 hours after treatment were excluded.
Results: We identiﬁed 144 lysis procedures, and 53 were treated with
the AngioJet. Average age was 50 (range, 87-20; median, 49). Arterial
thrombus was the indication in 68%; venous in the rest. AKI occurred in 15Table. Multivariate analysis of preoperative factors affecting outcomes with low
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BMI, Body mass index; CAD, coronary artery disease; CI, conﬁdence interval; Cof 53 (28%). Baseline Cr in AKI and non-AKI patients was similar, whereas
Cr after AngioJet was not (P ¼ .01). Only four patients had a baseline Cr
>1.4 (two in each group). Average age of the AKI group was 54 (range 36-
74, medium 49), 47% were male, and only one had a baseline Cr >1.4 mg/
dL (not signiﬁcant for all). Average creatinine increase from baseline in AKI
group was 0.5 mg/dL (167% rise; P ¼ .003) compared with e0.07mg/dL
(NS) in non-AKI patients. When compared with 53 lysis cases that did not
use AngioJet, the Cr change in the AngioJet group was higher (P ¼ .03).
Conclusions: This preliminary study suggests that AKI may occur in
more than one-quarter of patients treated with the AngioJet, independently of
traditional risk factors for AKI (diabetes, baseline Cr, and age). This risk may
be due to hemolysis and is under-reported in the literature. Prospective studies
and long-term consequences should be undertaken to better deﬁne this risk.
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Objectives: We have previously reported trends of decreasing amputa-
tions along with increasing endovascular interventions for peripheral arterial dis-
ease (PAD) in a deﬁned population between 1990 and 2009. The aim of this
studywas to analyzepreoperative risk factors affectingoutcomes in thesepatients.
Methods: A retrospective cohort study of residents of a single
county was conducted. Procedures were identiﬁed by International Clas-
siﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-
CM)/Current Procedural Terminology codes and data collecteder extremity revascularization procedures
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OPD, chronic obstructive pulmonary disease; HR, hazard ratio.
